Newbridge Financial Services Group’s Intellia Therapeutics NTLA Stock Holding History

Newbridge Financial Services Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	11,925 +2,500	+27%	+$35K	0.03%	246
2026 Q1	$121K	Hold	9,425	–	–	0.02%	286
2025 Q4	$84.7K	Buy	9,425 +2,975	+46%	+$41K	0.01%	339
2025 Q3	$111K	Buy	6,450 +950	+17%	+$11.7K	0.02%	379
2025 Q2	$51.6K	Buy	+5,500	New	+$45.2K	0.01%	500
2023 Q3	–	Sell	-21	Closed	-$815	–	1372
2023 Q2	$856	Hold	21	–	–	﹤0.01%	1231
2023 Q1	$783	Hold	21	–	–	﹤0.01%	1292
2022 Q4	$733	Hold	21	–	–	﹤0.01%	1327
2022 Q3	$1K	Sell	21 -36	-63%	-$2.23K	﹤0.01%	1316
2022 Q2	$3K	Sell	57 -719	-93%	-$36.5K	﹤0.01%	1117
2022 Q1	$56K	Buy	776 +256	+49%	+$21.7K	0.03%	447
2021 Q4	$61K	Buy	520 +484	+1,344%	+$60.6K	0.03%	411
2021 Q3	$5K	Sell	36 -24	-40%	-$3.63K	﹤0.01%	1015
2021 Q2	$10K	Hold	60	–	–	0.01%	985
2021 Q1	$5K	Buy	+60	New	+$4.03K	﹤0.01%	1033

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Newbridge Financial Services Group's NTLA Position: Q2 2026 in Review

Newbridge Financial Services Group increased its Intellia Therapeutics (NTLA) stake by 27% in Q2 2026, buying an estimated $35K and bringing the position to 11,925 shares worth $202K. The position accounts for 0.03% of the portfolio, ranked #246.

Newbridge Financial Services Group first reported a position in NTLA in Q1 2021 and has held it in 15 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Newbridge Financial Services Group held 11,925 shares of Intellia Therapeutics worth $202K as of Q2 2026.
Newbridge Financial Services Group bought 2,500 Intellia Therapeutics shares in Q2 2026, an estimated $35K.
Intellia Therapeutics made up 0.03% of Newbridge Financial Services Group's portfolio in Q2 2026, its #246 holding.
Newbridge Financial Services Group first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 15 quarters since.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.